-
Bullish Mizuho Says Bausch Health's Long-Term Guidance 'Within Reach'
Monday, March 18, 2019 - 10:35am | 378Read More...Bausch Health Companies Inc’s (NYSE: BHC) growth drivers will become “more tangible” in 2019, and shares could appreciate as the company continues to demonstrate good execution, according to Mizuho Securities. The Analyst Mizuho’s Irina Koffler maintained a Buy rating...
-
Teva's Cost-Cutting Plan Nets A Mizuho Upgrade
Tuesday, January 9, 2018 - 11:56am | 455Read More...After a turbulent 2017, Mizuho analysts now see upside potential for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock. The Analyst Mizuho Securities USA's Irina Koffler upgraded Teva's stock rating from Neutral to Buy with a price target boosted from $16 to $23. The...
-
Valeant's Post-Ackman Recovery Is Characterized By 'Less Money, More Problems'
Tuesday, March 21, 2017 - 10:02am | 421Read More...Billionaire investor Bill Ackman cut his losses in Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s stock so now is the time for both the company and hedge fund manager to move on. According to a Bloomberg report, Valeant's path forward is difficult and characterized by the company having less money...
-
What's Left Of Valeant's Assets After This Morning's Sale?
Tuesday, January 10, 2017 - 12:59pm | 381Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares were seen soaring 9.3 percent on Tuesday after the company announced the sale of $2.1 billion in assets to raise money to pay down the company’s staggering $30 billion debt load. Divestitures Valeant sold skincare brands CeraVe, AcneFree and...
-
Mizuho Downgrades Relypsa, Says Near-Term Takeout 'Unlikely'
Wednesday, May 4, 2016 - 1:30pm | 375Read More...Relypsa Inc (NASDAQ: RLYP) shares plunged more than 18 percent after Mizuho Securities downgraded the stock to Underperform from Neutral, saying the near-term buyout of the company is "unlikely" following its recent $150 million debt offering. "We view this event (offering) as a sign that near-term...
-
Mizuho On Relypsa: Management's Body Language Suggests Deal Talks May Not Be Imminent, Stock Could Fall Below $10
Friday, April 15, 2016 - 1:05pm | 317Read More...The future of Relypsa Inc (NASDAQ: RLYP)’s share price may hinge entirely on a potential buyout. In fact, if the rumored buyout doesn’t end up happening, Mizuho analyst Irina Koffler believes Relypsa’s stock is headed for single-digits. Relypsa’s stock skyrocketed 67...
-
Analysts Mixed Following Valeant's Latest Developments
Tuesday, April 5, 2016 - 2:17pm | 511Read More...Investors of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) had several developments to play with on Tuesday regarding the embattled pharma company. The company announced the ad hoc committee of the board of directors have completed the accounting review, including various Philidor matters, and...
-
Mizuho's Valeant Calculation: DCF + SOTP = $18/Share
Monday, March 21, 2016 - 10:54am | 315Read More...News of Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s downgrade at Mizuho is circling Wall Street on Monday, largely because of the firm's Street-low price target of $18 per share. How did Mizuho get to this valuation? Let's take a look. According to analysis from Irina Koffler,...
-
How To Invest During Biotech's Latest Crisis
Friday, October 9, 2015 - 11:25am | 554Read More...Shares of the biotechnology ETF, iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB), have lost more than 15 percent over the past three months. The sector has been hard hit following a "drug pricing crisis," according to Irina Koffler of Mizuho Securities who initiated coverage...
-
Cantor Fitzgerald Downgrades Hyperion After Acquisition
Tuesday, March 31, 2015 - 9:37am | 230Read More...Cantor Fitzgerald on Tuesday issued a company update on Hyperion Therapeutics Inc (NASDAQ: HPTX) after Horizon Pharma PLC (NASDAQ: HZNP) announced that it plans to acquire Hyperion for $46 per share in cash. Cantor Fitzgerald downgraded Hyperion to Hold and increased its price target from $35 to $...
